Show simple item record

dc.contributor.authorCantor, Charles
dc.date.accessioned2010-11-16T19:02:33Z
dc.date.available2010-11-16T19:02:33Z
dc.date.issued2010-11-09
dc.identifier.urihttp://hdl.handle.net/1853/35984
dc.descriptionCharles Cantor, Chief Scientific Officer, Sequenom, Inc. and Professor, Biomedical Engineering, Boston University and Professor of Pharmacology, School of Medicine, Boston University, presented a lecture on Tuesday, November 9, 2010, 11:00AM in Room 1116E of the Klaus auditorium on the Georgia Tech Campus.en_US
dc.descriptionCharles Cantor is a founder, and Chief Scientific Officer at SEQUENOM, Inc. He is also founder of SelectX Pharmaceuticals, a drug discovery company based in the Boston area; Retrotope, an anti-aging company; and DiThera, a biotherapeutic company. He is co-director of the Center for Advanced Biotechnology at Boston University, and professor emeritus of Biomedical Engineering. Dr. Cantor has held positions at Columbia University and University of California at Berkeley, and was also director of the Human Genome Center of the Department of Energy at Lawrence Berkeley Laboratory. He has published more than 450 peer-reviewed articles, has been granted more than 60 patents. He co-authored a three-volume textbook on Biophysical Chemistry and the first textbook on Genomics: The Science and Technology of the Human Genome Project. He sits on the advisory boards of more than 15 national and international organizations and is a member of the National Academy of Sciences.
dc.descriptionRuntime: 59:10 minutes
dc.description.abstractIn this talk I will describe three circumstances where sensitive detection of nucleic acids leads to practical or useful results. All display synergy between academic research and biotechnology companies. The first, involving SEQUENOM in San Diego, uses both mass spectrometry of DNA and high throughput sequencing of DNA to detect traces of fetal DNA that are present n the peripheral blood of a pregnant woman. This allows prenatal diagnosis of fetal traits to be performed without any risk at all to mother or fetus. The second involving DiThera, in Costa Mesa, demonstrates schemes for the detection of specific RNA sequences in living cells. This provides a field of the dynamics of RNA synthesis and decay and offers the potential for the development of diagnostics and therapeutics based on RNA sequence alone. The third project uses technology developed by SelectX Pharmaceuticals, an antibiotic development company in Worcester Mass. Select X has safe technology to subject growing cultures to continuously increasing antibiotic stress. Using this technology and both protein and nucleic acid mass spectrometry the unusual discovery was recently made that some cells in culture at a cost to their own fitness, are able to help other cells to have enhanced antibiotic resistance. This shows that even in the simplest bacteria altruistic behavior is possible.en_US
dc.format.extent59:10 minutes
dc.language.isoen_USen_US
dc.publisherGeorgia Institute of Technologyen_US
dc.subjectNon-invasive prenatal diagnosticsen_US
dc.subjectStochastic noiseen_US
dc.subjectDetection of RNA in living cellsen_US
dc.subjectBacterial altruismen_US
dc.titleDetecting specific nucleic acid sequences under challenging but potentially useful circumstancesen_US
dc.typeLectureen_US
dc.typeVideoen_US
dc.contributor.corporatenameSequenom
dc.contributor.corporatenameBoston University. School of Biomedical Engineering
dc.contributor.corporatenameBoston University. School of Medicine


Files in this item

This item appears in the following Collection(s)

Show simple item record